CLRB News and Press, Cellectar Biosciences Inc. From 06/04/21

Cellectar Biosciences shares slide ([[CLRB]] -13.2%) after posting data from its mid-stage study of CLR 131 in patients with Waldenstrom’s macroglobulinemia ((WM)), a rare and incurable disease, at the American Society of Clinical Oncology ((ASCO)) Annual meeti...

Gainers: Windtree Therapeutics (WINT) +57%, Senseonics (SENS) +38%, Ra Medical Systems (RMED) +22%, Cullinan Oncology (CGEM) +20%, Progenity (PROG) +10%.Losers: Harpoon Therapeutics (HARP) -25%, Purple Biotech (PPBT) -19%, Adamis Pha...

Mean treatment free remission 1.1 years and remains ongoing Progression free survival for MYD88 wild type and high-risk patients 18 months and ongoing FLORHAM PARK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! Let’s get ready for another busy day of trading with a look at the biggest pre-market stock movers for Wednesday. Source: ventdusud / Shutterstock.com But before that. It’s important to m...

FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a poster presentation at the American Society ...

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available ...

Cellectar Biosciences (CLRB): Q1 GAAP EPS of -$0.13 beats by $0.03.Cash and cash equivalents of $53.63M.Press Release For further details see: Cellectar Biosciences EPS beats by $0.03

Initiated pivotal study of CLR 131 in Waldenstrom’s macroglobulinemia (WM) Received European Orphan Drug Designation for CLR 131 in WM Strong cash position of approximately $54 million providing cash runway into Q3 2023 FLORHAM PARK, N.J., May 10, 2021 (GLOBE NE...

Cellectar Biosciences (CLRB) announces that it has received notification of formal grant of the patent titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" by the Eurasian, Australian and Mexican patent authorities.The patent provides composition of matter and use prote...

FLORHAM PARK, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has received noti...